| Subgroups |
| Metastatic | Locally Advanced | p-value (Mantel Cox Log Rank Test) | ||||
| PR | SD | PD | PR | SD | PD | |||
| Hormonal Subtypes | ERPR-Her2+ | 8/17 (47%) | 6/17 (35%) | 3/17 (17.8%) | 13/17 (76.4%) | 2/17 (11.7%) | 2/17 (11.7%) | 0.190 |
| Triple Positive | 4/9 (44.4%) | 2/9 (22.2%) | 3/9 (33.3%) | 17/22 (77.2%) | 1/22 (4.5%) | 4/22 (18.1%) | ||
| Trastuzumab | Herclone/Biceltis | 11/20 (55%) | 5/20 (25%) | 4/20 (20%) | 21/24 (87.5%) | 2/24 (8.3%) | 1/24 (4.1%) | 0.520 |
| Canmab | 1/6 (16.6%) | 3/6 (50%) | 2/6 (33.3%) | 9/15 (60%) | 1/15 (6.6%) | 5/15 (33.3%) | ||
| Overall | response | 12/26 (46.1%) | 8/26 (30%) | 6/26 (23.8%) | 30/39 (76%) | 3/39 (7.2%) | 6/39 (15%) | 0.368 |